Immunomodulatory effects of interferons in malignancies
Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an i...
Gespeichert in:
| Veröffentlicht in: | Journal of interferon & cytokine research 2013-04, Vol.33 (4), p.154-161 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | 4 |
| container_start_page | 154 |
| container_title | Journal of interferon & cytokine research |
| container_volume | 33 |
| creator | Bekisz, Joseph Sato, Yuki Johnson, Chase Husain, Syed R Puri, Raj K Zoon, Kathryn C |
| description | Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an increase in their survival time. Subsequent studies with purified IFNs confirmed the direct and indirect stimulation of immune cells, resulting in antitumor activities of IFN. Clinically, IFN-alphas (αs) have been shown to have activity against a variety of tumors. Initially, the U.S. Food and Drug Administration licensed 2 recombinant IFN-αs for the treatment of hairy-cell leukemia and then later for several other cancers. The success rate seen with IFNs and certain tumors has been varied. Unfortunately, some neoplasms show no response to IFN. Monocytes/macrophages play an important role in cancer progression. Monocytes in combination with IFN may be an important therapy for several cancers. This article focuses on the role of IFN and monocytes alone or in combination in affecting malignancies. |
| doi_str_mv | 10.1089/jir.2012.0167 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3647483</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2992514331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-ee8a39ccfc265b00953437e939b975425a35b4f8b8a890f3b413bc7cd7bffca73</originalsourceid><addsrcrecordid>eNpdkUtLAzEURoMoVqtLtzLgxs3UZPLeCFJ8FApudB0yaVKnzCQ1mRH6701pLerqfnAPH_dyALhCcIKgkHerJk4qiKoJRIwfgTNEKS85YfQ4Z8hlKSXkI3Ce0gpCyEQlT8GowpRDLNAZ4LOuG3zowmJodR_iprDOWdOnIrii8b2NzsbgU85Fp9tm6bU3jU0X4MTpNtnL_RyD96fHt-lLOX99nk0f5qUhiPaltUJjaYwzFaM1hJJigrmVWNaSU1JRjWlNnKiFFhI6XBOEa8PNgtfOGc3xGNzvetdD3dmFsb6PulXr2HQ6blTQjfq78c2HWoYvhRnhROBccLsviOFzsKlXXZOMbVvtbRiSQrhiiCDOREZv_qGrMESf38sUY5iKiqJMlTvKxJBStO5wDIJqq0RlJWqrRG2VZP769wcH-scB_gbJfIg9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1366358251</pqid></control><display><type>article</type><title>Immunomodulatory effects of interferons in malignancies</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bekisz, Joseph ; Sato, Yuki ; Johnson, Chase ; Husain, Syed R ; Puri, Raj K ; Zoon, Kathryn C</creator><creatorcontrib>Bekisz, Joseph ; Sato, Yuki ; Johnson, Chase ; Husain, Syed R ; Puri, Raj K ; Zoon, Kathryn C</creatorcontrib><description>Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an increase in their survival time. Subsequent studies with purified IFNs confirmed the direct and indirect stimulation of immune cells, resulting in antitumor activities of IFN. Clinically, IFN-alphas (αs) have been shown to have activity against a variety of tumors. Initially, the U.S. Food and Drug Administration licensed 2 recombinant IFN-αs for the treatment of hairy-cell leukemia and then later for several other cancers. The success rate seen with IFNs and certain tumors has been varied. Unfortunately, some neoplasms show no response to IFN. Monocytes/macrophages play an important role in cancer progression. Monocytes in combination with IFN may be an important therapy for several cancers. This article focuses on the role of IFN and monocytes alone or in combination in affecting malignancies.</description><identifier>ISSN: 1079-9907</identifier><identifier>EISSN: 1557-7465</identifier><identifier>DOI: 10.1089/jir.2012.0167</identifier><identifier>PMID: 23570381</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Animals ; Cytokines - metabolism ; Humans ; Immunomodulation - drug effects ; Interferon Type I - therapeutic use ; Interferon-gamma - therapeutic use ; Leukocytes, Mononuclear - immunology ; Macrophages - immunology ; Mice ; Neoplasms - drug therapy ; Neoplasms - immunology ; Reviews</subject><ispartof>Journal of interferon & cytokine research, 2013-04, Vol.33 (4), p.154-161</ispartof><rights>(©) Copyright 2013, Mary Ann Liebert, Inc.</rights><rights>Copyright 2013, Mary Ann Liebert, Inc. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-ee8a39ccfc265b00953437e939b975425a35b4f8b8a890f3b413bc7cd7bffca73</citedby><cites>FETCH-LOGICAL-c415t-ee8a39ccfc265b00953437e939b975425a35b4f8b8a890f3b413bc7cd7bffca73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23570381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bekisz, Joseph</creatorcontrib><creatorcontrib>Sato, Yuki</creatorcontrib><creatorcontrib>Johnson, Chase</creatorcontrib><creatorcontrib>Husain, Syed R</creatorcontrib><creatorcontrib>Puri, Raj K</creatorcontrib><creatorcontrib>Zoon, Kathryn C</creatorcontrib><title>Immunomodulatory effects of interferons in malignancies</title><title>Journal of interferon & cytokine research</title><addtitle>J Interferon Cytokine Res</addtitle><description>Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an increase in their survival time. Subsequent studies with purified IFNs confirmed the direct and indirect stimulation of immune cells, resulting in antitumor activities of IFN. Clinically, IFN-alphas (αs) have been shown to have activity against a variety of tumors. Initially, the U.S. Food and Drug Administration licensed 2 recombinant IFN-αs for the treatment of hairy-cell leukemia and then later for several other cancers. The success rate seen with IFNs and certain tumors has been varied. Unfortunately, some neoplasms show no response to IFN. Monocytes/macrophages play an important role in cancer progression. Monocytes in combination with IFN may be an important therapy for several cancers. This article focuses on the role of IFN and monocytes alone or in combination in affecting malignancies.</description><subject>Animals</subject><subject>Cytokines - metabolism</subject><subject>Humans</subject><subject>Immunomodulation - drug effects</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Macrophages - immunology</subject><subject>Mice</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><subject>Reviews</subject><issn>1079-9907</issn><issn>1557-7465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkUtLAzEURoMoVqtLtzLgxs3UZPLeCFJ8FApudB0yaVKnzCQ1mRH6701pLerqfnAPH_dyALhCcIKgkHerJk4qiKoJRIwfgTNEKS85YfQ4Z8hlKSXkI3Ce0gpCyEQlT8GowpRDLNAZ4LOuG3zowmJodR_iprDOWdOnIrii8b2NzsbgU85Fp9tm6bU3jU0X4MTpNtnL_RyD96fHt-lLOX99nk0f5qUhiPaltUJjaYwzFaM1hJJigrmVWNaSU1JRjWlNnKiFFhI6XBOEa8PNgtfOGc3xGNzvetdD3dmFsb6PulXr2HQ6blTQjfq78c2HWoYvhRnhROBccLsviOFzsKlXXZOMbVvtbRiSQrhiiCDOREZv_qGrMESf38sUY5iKiqJMlTvKxJBStO5wDIJqq0RlJWqrRG2VZP769wcH-scB_gbJfIg9</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Bekisz, Joseph</creator><creator>Sato, Yuki</creator><creator>Johnson, Chase</creator><creator>Husain, Syed R</creator><creator>Puri, Raj K</creator><creator>Zoon, Kathryn C</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201304</creationdate><title>Immunomodulatory effects of interferons in malignancies</title><author>Bekisz, Joseph ; Sato, Yuki ; Johnson, Chase ; Husain, Syed R ; Puri, Raj K ; Zoon, Kathryn C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-ee8a39ccfc265b00953437e939b975425a35b4f8b8a890f3b413bc7cd7bffca73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Cytokines - metabolism</topic><topic>Humans</topic><topic>Immunomodulation - drug effects</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Macrophages - immunology</topic><topic>Mice</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bekisz, Joseph</creatorcontrib><creatorcontrib>Sato, Yuki</creatorcontrib><creatorcontrib>Johnson, Chase</creatorcontrib><creatorcontrib>Husain, Syed R</creatorcontrib><creatorcontrib>Puri, Raj K</creatorcontrib><creatorcontrib>Zoon, Kathryn C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of interferon & cytokine research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bekisz, Joseph</au><au>Sato, Yuki</au><au>Johnson, Chase</au><au>Husain, Syed R</au><au>Puri, Raj K</au><au>Zoon, Kathryn C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunomodulatory effects of interferons in malignancies</atitle><jtitle>Journal of interferon & cytokine research</jtitle><addtitle>J Interferon Cytokine Res</addtitle><date>2013-04</date><risdate>2013</risdate><volume>33</volume><issue>4</issue><spage>154</spage><epage>161</epage><pages>154-161</pages><issn>1079-9907</issn><eissn>1557-7465</eissn><abstract>Investigation of the antitumor and immunomodulatory activities of interferon (IFN) began shortly after the cytokine was discovered in 1957. Early work showed a direct correlation between administration of IFN and inhibition of symptoms associated with virally induced leukemia in mice as well as an increase in their survival time. Subsequent studies with purified IFNs confirmed the direct and indirect stimulation of immune cells, resulting in antitumor activities of IFN. Clinically, IFN-alphas (αs) have been shown to have activity against a variety of tumors. Initially, the U.S. Food and Drug Administration licensed 2 recombinant IFN-αs for the treatment of hairy-cell leukemia and then later for several other cancers. The success rate seen with IFNs and certain tumors has been varied. Unfortunately, some neoplasms show no response to IFN. Monocytes/macrophages play an important role in cancer progression. Monocytes in combination with IFN may be an important therapy for several cancers. This article focuses on the role of IFN and monocytes alone or in combination in affecting malignancies.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>23570381</pmid><doi>10.1089/jir.2012.0167</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1079-9907 |
| ispartof | Journal of interferon & cytokine research, 2013-04, Vol.33 (4), p.154-161 |
| issn | 1079-9907 1557-7465 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3647483 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Cytokines - metabolism Humans Immunomodulation - drug effects Interferon Type I - therapeutic use Interferon-gamma - therapeutic use Leukocytes, Mononuclear - immunology Macrophages - immunology Mice Neoplasms - drug therapy Neoplasms - immunology Reviews |
| title | Immunomodulatory effects of interferons in malignancies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A38%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunomodulatory%20effects%20of%20interferons%20in%20malignancies&rft.jtitle=Journal%20of%20interferon%20&%20cytokine%20research&rft.au=Bekisz,%20Joseph&rft.date=2013-04&rft.volume=33&rft.issue=4&rft.spage=154&rft.epage=161&rft.pages=154-161&rft.issn=1079-9907&rft.eissn=1557-7465&rft_id=info:doi/10.1089/jir.2012.0167&rft_dat=%3Cproquest_pubme%3E2992514331%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1366358251&rft_id=info:pmid/23570381&rfr_iscdi=true |